PH12019500949A1 - Ror-gamma modulators - Google Patents

Ror-gamma modulators

Info

Publication number
PH12019500949A1
PH12019500949A1 PH12019500949A PH12019500949A PH12019500949A1 PH 12019500949 A1 PH12019500949 A1 PH 12019500949A1 PH 12019500949 A PH12019500949 A PH 12019500949A PH 12019500949 A PH12019500949 A PH 12019500949A PH 12019500949 A1 PH12019500949 A1 PH 12019500949A1
Authority
PH
Philippines
Prior art keywords
ror
modulators
gamma modulators
disorders
gamma
Prior art date
Application number
PH12019500949A
Other languages
English (en)
Inventor
Raju Mohan
John Nuss
Jason Harris
Original Assignee
Escalier Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escalier Biosciences Bv filed Critical Escalier Biosciences Bv
Publication of PH12019500949A1 publication Critical patent/PH12019500949A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
PH12019500949A 2016-10-27 2019-04-26 Ror-gamma modulators PH12019500949A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (1)

Publication Number Publication Date
PH12019500949A1 true PH12019500949A1 (en) 2019-08-05

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500949A PH12019500949A1 (en) 2016-10-27 2019-04-26 Ror-gamma modulators

Country Status (14)

Country Link
US (5) US10905687B2 (cg-RX-API-DMAC10.html)
EP (1) EP3532062B1 (cg-RX-API-DMAC10.html)
JP (1) JP7027437B2 (cg-RX-API-DMAC10.html)
KR (1) KR102598775B1 (cg-RX-API-DMAC10.html)
CN (1) CN110139652B (cg-RX-API-DMAC10.html)
AU (1) AU2017348345B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019008548A2 (cg-RX-API-DMAC10.html)
CA (1) CA3042080A1 (cg-RX-API-DMAC10.html)
ES (1) ES2928904T3 (cg-RX-API-DMAC10.html)
IL (1) IL266261B (cg-RX-API-DMAC10.html)
MX (1) MX392163B (cg-RX-API-DMAC10.html)
PH (1) PH12019500949A1 (cg-RX-API-DMAC10.html)
RU (1) RU2753490C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018081558A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ,ビーブイ 二環式RORγモジュレーター
EA202092051A1 (ru) 2018-03-12 2021-03-04 Эскальер Байосайенсес Б.В. Спироциклические модуляторы ror-гамма
AU2020378005A1 (en) * 2019-11-05 2022-05-26 Dermira, Inc. ROR gamma T inhibitors and topical uses thereof
IL298928A (en) * 2020-06-30 2023-02-01 Dermira Inc RORγt INHIBITORS AND TOPICAL USES THEREOF
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) * 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
PT2758060T (pt) * 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
AR092348A1 (es) * 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
CN107614062A (zh) * 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma

Also Published As

Publication number Publication date
EP3532062A1 (en) 2019-09-04
MX2019004973A (es) 2019-09-19
IL266261A (en) 2019-06-30
RU2019115059A3 (cg-RX-API-DMAC10.html) 2020-12-18
IL266261B (en) 2022-07-01
AU2017348345A1 (en) 2019-05-30
MX392163B (es) 2025-03-21
US10905687B2 (en) 2021-02-02
KR20190096979A (ko) 2019-08-20
US20220175765A1 (en) 2022-06-09
CN110139652A (zh) 2019-08-16
AU2017348345B2 (en) 2022-01-27
US20230277527A1 (en) 2023-09-07
ES2928904T3 (es) 2022-11-23
RU2019115059A (ru) 2020-11-27
EP3532062B1 (en) 2022-07-20
BR112019008548A2 (pt) 2019-09-17
WO2018081558A1 (en) 2018-05-03
EP3532062A4 (en) 2020-04-15
JP7027437B2 (ja) 2022-03-01
US20240216361A1 (en) 2024-07-04
US20190269674A1 (en) 2019-09-05
CA3042080A1 (en) 2018-05-03
RU2753490C2 (ru) 2021-08-17
JP2019535813A (ja) 2019-12-12
CN110139652B (zh) 2022-10-11
KR102598775B1 (ko) 2023-11-03
US20210069182A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX392163B (es) Moduladores de ror gamma.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
NZ737399A (en) Ccr2 modulators
CL2016001364A1 (es) Moduladores de ror gamma (rory)
MY188139A (en) Sodium channel modulators for the treatment of pain
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
MX385357B (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX378098B (es) Derivados de piperazina como moduladores de ror?.
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
BR112021014566A2 (pt) Moduladores de gpr35
MX379440B (es) Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos.